Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Nab-paclitaxel + Tinengotinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nab-paclitaxel | Abraxane | ABI-007|Paclitaxel Protein-bound | Chemotherapy - Taxane 3 | Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary). |
Tinengotinib | TT00420|TT 00420|TT-00420 | Aurka Inhibitors 27 Aurkb Inhibitors 21 CSF1R Inhibitor 28 FGFR1 Inhibitor 28 FGFR2 Inhibitor 23 FGFR3 Inhibitor 19 JAK Inhibitor (Pan) 9 VEGFR Inhibitor (Pan) 36 | Tinengotinib (TT-00420) is a multikinase inhibitor that targets AURKA, AURKB, FGFR1-3, VEGFR, JAK1/2, and CSF1R, potentially resulting in decreased cell proliferation and inhibition of tumor growth (PMID: 36223547). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04742959 | Phase Ib/II | Tinengotinib Nab-paclitaxel + Tinengotinib | Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | Completed | USA | 0 |